Logotype for PeptiDream Inc

PeptiDream (4587) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for PeptiDream Inc

Q3 2026 earnings summary

11 Nov, 2026

Executive summary

  • Nine-month revenue rose 15.3% YoY to ¥14,820 million; operating loss narrowed to ¥2,867 million and net loss attributable to owners narrowed to ¥2,363 million.

  • Full-year 2026 guidance remains unchanged, with revenue of ¥32,000 million and operating profit of ¥4,600 million; second-half upfront and R&D milestone revenue is expected to support full-year operating profit.

Financial highlights

  • Revenue increased by ¥1,963 million YoY to ¥14,820 million; gross profit rose to ¥6,960 million from ¥4,835 million.

  • Operating loss narrowed by ¥1,191 million YoY to ¥2,867 million; core operating loss narrowed by ¥1,175 million to ¥2,804 million.

  • Loss before tax was ¥3,154 million versus ¥4,340 million YoY; net loss was ¥2,363 million versus ¥3,217 million, and basic EPS was -¥18.35 versus -¥24.88.

  • Finance costs were ¥429 million, versus finance income of ¥146 million; income tax benefit was ¥791 million.

Outlook and guidance

  • FY2026 forecast: revenue ¥32,000 million, core operating profit ¥4,600 million, operating profit ¥4,600 million, profit before tax ¥4,300 million and net profit ¥3,000 million; guidance unchanged.

  • Full-year operating profit is expected to be supported by upfront payments under drug discovery and development agreements and R&D milestone revenue in H2.

  • FY2026 forecasts include capital expenditures of ¥5,449 million, depreciation of ¥1,922 million, R&D expenses of ¥6,445 million and period-end headcount of 810.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from PeptiDream